Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis

European Journal of Immunology

Volumn 37, Issue 12, 2007, Pages 3576-3581

  Leech, Melanie D ^a   Chung, Chen Yen ^a   Culshaw, Abigail ^a   Anderton, Stephen M ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Anaphylaxis; Autoimmunity; Multiple sclerosis; T cells; Tolerance

Indexed keywords

ALTERED PEPTIDE LIGAND; AUTOANTIGEN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PEPTIDE ANTIBODY; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; STRUCTURE ANALYSIS; T LYMPHOCYTE; TOXICITY TESTING;

ANAPHYLAXIS; ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; BINDING SITES; DESENSITIZATION, IMMUNOLOGIC; DRUG EVALUATION, PRECLINICAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPITOPES, T-LYMPHOCYTE; FEMALE; GLYCOPROTEINS; IMMUNE TOLERANCE; IMMUNIZATION; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; SPECIFIC PATHOGEN-FREE ORGANISMS; T-CELL ANTIGEN RECEPTOR SPECIFICITY;

EID: 37549045964     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200737148     Document Type: Article

References (19)

1. Anderton, S. M., Peptide-based immunotherapy of autoimmunity: A path of puzzles, paradoxes and possibilities. Immunology 2001. 104: 367-376.
2. Larche, M. and Wraith, D. C., Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 2005. 11: S69-76.
3. Prakken, B. J., Samodal, R., Le, T. D., Giannoni, F., Yung, G. P., Scavulli, J., Amox, D. et al., Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 2004. 101: 4228-4233.
4. Pedotti, R., Mitchell, D., Wedemeyer, J., Karpuj, M.,, Chabas, D., Hattab, E. M., Tsai, M. et al., An unexpected version of horror autotoxicus: Anaphylactic shock to a self-peptide. Nat. Immunol. 2001. 2: 216-222.
5. Pedotti, R., Sanna, M., Tsai, M., DeVoss, J., Steinman, L., McDevitt, H. and Galli, S. J., Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus. BMC immunology 2003. 4: 2.
6. Smith, C. E., Eagar, T. N., Strominger, J. L. and Miller, S. D., Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 2005. 102: 9595-9600.
7. Liu, E., Moriyama, H., Abiru, N., Miao, D., Yu, L., Taylor, R. M., Finkelman, F. D. and Eisenbarth, G. S., Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J. Clin. Invest. 2002. 110: 1021-1027.
8. Kappos, L., Comi, G., Panitch, H., Oger, J., Antel, J., Conlon, P. and Steinman, L., Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The altered peptide ligand in relapsing MS study group. Nat. Med. 2000. 6: 1176-1182.
9. Sloan-Lancaster, J. and Allen, P. M., Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 1996. 14: 1-27.
10. Mendel, I., Kelero de Rosbo, N. and Ben-Nun, A., A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2(B) mice - fine specificity and T-cell receptor V-beta expression of encephalitogenic T-cells. Eur. J. Immunol. 1995. 25: 1951-1959.
11. Mendel, I., Kelero de Rosbo, N. K. and Ben-Nun, A., Delineation of the minimal encephalitogenic epitope within the immunodominant region of myelin oligodendrocyte glycoprotein: Diverse VP gene usage by T cells recognizing the core epitope encephalitogenic for T cell receptor V beta(b) and T cell receptor V beta(a) H-2(b) mice. Eur. J. Immunol. 1996. 26: 2470-2479.
12. Hochweller, K., Sweenie, C. H. and Anderton, S. M., Immunological tolerance using synthetic peptides - Basic mechanism and clinical application. Curr. Molec. Med. 2006. 6: 631-643.
13. Strait, R. T., Morris, S. C., Yang, M., Qu, X.-W. and Finkelman, F. D., Pathways of anaphylaxis in the mouse. J. Allerg. Clin. Immunol. 2002. 109: 658-668.
14. Anderton, S. M., Kissler, S., Lamont, A. G. and Wraith, D. C., Therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells. Eur. J. Immunol. 1999. 29: 1850-1857.
15. Nicholson, L. B., Greer, J. M., Sobel, R. A., Lees, M. B. and Kuchroo, V. K., An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995. 3: 397-405.
16. Margot, C. D., Ford, M. L. and Evavold, B. D., Amelioration of established experimental autoimmune encephalomyelitis by an MHC anchor-substituted variant of proteolipid protein 139-151. J. Immunol. 2005. 174: 3352-3358.
17. Gentilucci, L., Tolomelli, A. and Squassabia, F., Peptides and peptido-mimetics in medicine, surgery and biotechnology. Curr. Medicin. Chem. 2006. 13: 2449-2466.
18. Sweenie, C. H., Mackenzie, K. J., Rone-Orugboh, A., Liu, M. and Anderton, S. M., Distinct T cell recognition of naturally processed and cryptic epitopes within the immunodominant 35-55 region of myelin oligodendrocyte glycoprotein. J. Neuroimmunol. 2007. 183: 7-16.
19. + regulatory cells within the central nervous system. J. Immunol. 2005. 175: 3025-3032.